Chembio Diagnostics Inc  

(Public, NASDAQ:CEMI)   Watch this stock  
Find more results for CEMI
-0.08 (-2.17%)
Jan 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.52 - 3.72
52 week 2.83 - 5.20
Open 3.72
Vol / Avg. 122,702.00/47,384.00
Mkt cap 34.60M
P/E     -
Div/yield     -
EPS -0.10
Shares 9.61M
Beta 0.10
Inst. own 18%
Mar 4, 2015
Q4 2014 Chembio Diagnostics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 13, 2015
Chembio Diagnostics Inc at EBD Biotech Showcase
Nov 6, 2014
Q3 2014 Chembio Diagnostics Inc Earnings Call
Nov 6, 2014
Q3 2014 Chembio Diagnostics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -3.70% 1.80%
Operating margin -3.59% 3.40%
EBITD margin - 5.46%
Return on average assets -4.52% 2.54%
Return on average equity -5.38% 3.12%
Employees 206 -
CDP Score - -


3661 Horseblock Road
United States - Map
+1-631-9241135 (Phone)
+1-775-8849383 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Chembio Diagnostics, Inc. develops, manufactures and markets rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company�s main products are four rapid tests for the detection of human immunodeficiency virus (HIV) antibodies. Three of these products employ lateral flow technology, can be used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format, and a barrel format. The tests employing the cassette and barrel formats were approved by the United States Food and Drug Administration (FDA) and are distributed by Inverness Medical Innovations, Inc. (Inverness) in the United States. Its fourth rapid HIV test, which is developed on its Dual Path Platform (DPP) technology, detects antibodies to HIV in oral fluid samples, as well as all blood matrices.

Officers and directors

John J. Sperzel III President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Richard J. Larkin Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Sharon Klugewicz Chief Operating Officer
Age: 46
Bio & Compensation  - Reuters
Javan Esfandiari Sr. VP - Research and Development
Age: 47
Bio & Compensation  - Reuters
Tom Ippolito Vice President - Regulatory Affairs, Quality Assurance and Quality Control
Age: 50
Bio & Compensation  - Reuters
Paul Lambotte Ph.D. Vice President - Product Development
Bio & Compensation  - Reuters
Katherine L. Davis Non-Executive Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barbara A. DeBuono M.D., M.P.H. Independent Director
Age: 59
Bio & Compensation  - Reuters
Peter T. Kissinger Ph.D. Independent Director
Age: 69
Bio & Compensation  - Reuters
Gary Meller M.D. Independent Director
Age: 64
Bio & Compensation  - Reuters